Events & Presentations Events & Presentations Upcoming Events There are no upcoming events scheduled at this time. Past Events 9/13/21 at 7:00 AM EDT H.C. Wainwright 23rd Annual Global Investment Conference Click here for webcast 9/10/21 at 11:00 AM EDT Morgan Stanley 19th Annual Global Healthcare Conference Click here for webcast 6/23/21 at 8:00 AM EDT KER-050 Update Click here for webcast Supporting Materials KER-050 Update 1.1 MB Corporate Presentation Corporate Presentation June 2021 June 22, 2021 Corporate Presentation June 2021 1.9 MB Presentations KER-050 Update June 22, 2021 KER-050 Update 1.1 MB EHA2021 Virtual Congress June 11, 2021 KER-050, an inhibitor of TGF-β superfamily signaling, observed to have a rapid, dynamic, and durable effect on erythropoiesis 4.2 MB ALK2 is a potential therapeutic target in anemia resulting from chronic inflammation 1 MB ALK2 inhibition, a novel therapeutic approach to iron overload 1.5 MB Administration of ALK2 neutralizing antibodies to cynomolgus monkeys led to a sustained decrease in hepcidin, increase in circulating iron and increase in erythrocyte hemoglobin 1.2 MB 2021 ATS International Conference Presentation May 14, 2021 2021 ATS International Conference Presentation 646.8 KB European School of Haematology (ESH) 2nd Translational Research E-Conference March 5, 2021 KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production by Promoting Multiple Stages of Erythroid Differentiation 1.1 MB Targeted ALK2 Inhibition as a Therapeutic Approach to Reducing Hepcidin and Elevating Serum Iron 714.1 KB 62nd American Society of Hematology (ASH) Annual Meeting and Exposition December 7, 2020 KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production by Promoting Multiple Stages of Erythroid Differentiation 3.1 MB KER-050, a Modified ActRIIA Ligand Trap, Alleviates Cytopenia Arising from Multiple Etiologies 706 KB Administration of KER-047, a Novel ALK2 Inhibitor, Elicited Robust and Sustained Increases in Serum Iron in Healthy Participants 702.1 KB Selective Inhibition of ALK2 Signaling Suppresses Serum Hepcidin and Increases Serum Iron 797.8 KB ASBMR 2020 Annual Meeting Virtual Event September 11, 2020 KER-012, a Novel Activin Receptor Type II Ligand Trap Increased Bone in Mice via a Unique Mechanism of Action 1.5 MB 25th European Hematology Association (EHA) Congress (2020) June 12, 2020 Poster Presentation: Administration of KER-050, a Novel ActRIIA Ligand Trap, to Healthy Participants Elicited Robust and Sustained Increases in Hemoglobin and Platelets 1.3 MB Poster Presentation: Administration of KER-050, a Novel ActRIIA Ligand Trap, to Healthy Participants Elicited Robust and Sustained Increases in Hemoglobin and Platelets (Updated as of April 2021) 1.4 MB Poster Presentation: KER-050, a Novel Modified ActRIIA Ligand Trap, Increases Red Blood Cell Production in Cynomolgus Monkeys 1.3 MB Poster Presentation: KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production and is a Potential Candidate for the Treatment of Ineffective Erythropoiesis 1.1 MB Oral Presentation: Selective Inhibition of ALK2 Signaling Ameliorates Disease in a Novel Model of Iron Refractory Iron Deficiency Anemia (IRIDA) 2.5 MB
Events & Presentations Upcoming Events There are no upcoming events scheduled at this time. Past Events 9/13/21 at 7:00 AM EDT H.C. Wainwright 23rd Annual Global Investment Conference Click here for webcast 9/10/21 at 11:00 AM EDT Morgan Stanley 19th Annual Global Healthcare Conference Click here for webcast 6/23/21 at 8:00 AM EDT KER-050 Update Click here for webcast Supporting Materials KER-050 Update 1.1 MB Corporate Presentation Corporate Presentation June 2021 June 22, 2021 Corporate Presentation June 2021 1.9 MB Presentations KER-050 Update June 22, 2021 KER-050 Update 1.1 MB EHA2021 Virtual Congress June 11, 2021 KER-050, an inhibitor of TGF-β superfamily signaling, observed to have a rapid, dynamic, and durable effect on erythropoiesis 4.2 MB ALK2 is a potential therapeutic target in anemia resulting from chronic inflammation 1 MB ALK2 inhibition, a novel therapeutic approach to iron overload 1.5 MB Administration of ALK2 neutralizing antibodies to cynomolgus monkeys led to a sustained decrease in hepcidin, increase in circulating iron and increase in erythrocyte hemoglobin 1.2 MB 2021 ATS International Conference Presentation May 14, 2021 2021 ATS International Conference Presentation 646.8 KB European School of Haematology (ESH) 2nd Translational Research E-Conference March 5, 2021 KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production by Promoting Multiple Stages of Erythroid Differentiation 1.1 MB Targeted ALK2 Inhibition as a Therapeutic Approach to Reducing Hepcidin and Elevating Serum Iron 714.1 KB 62nd American Society of Hematology (ASH) Annual Meeting and Exposition December 7, 2020 KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production by Promoting Multiple Stages of Erythroid Differentiation 3.1 MB KER-050, a Modified ActRIIA Ligand Trap, Alleviates Cytopenia Arising from Multiple Etiologies 706 KB Administration of KER-047, a Novel ALK2 Inhibitor, Elicited Robust and Sustained Increases in Serum Iron in Healthy Participants 702.1 KB Selective Inhibition of ALK2 Signaling Suppresses Serum Hepcidin and Increases Serum Iron 797.8 KB ASBMR 2020 Annual Meeting Virtual Event September 11, 2020 KER-012, a Novel Activin Receptor Type II Ligand Trap Increased Bone in Mice via a Unique Mechanism of Action 1.5 MB 25th European Hematology Association (EHA) Congress (2020) June 12, 2020 Poster Presentation: Administration of KER-050, a Novel ActRIIA Ligand Trap, to Healthy Participants Elicited Robust and Sustained Increases in Hemoglobin and Platelets 1.3 MB Poster Presentation: Administration of KER-050, a Novel ActRIIA Ligand Trap, to Healthy Participants Elicited Robust and Sustained Increases in Hemoglobin and Platelets (Updated as of April 2021) 1.4 MB Poster Presentation: KER-050, a Novel Modified ActRIIA Ligand Trap, Increases Red Blood Cell Production in Cynomolgus Monkeys 1.3 MB Poster Presentation: KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production and is a Potential Candidate for the Treatment of Ineffective Erythropoiesis 1.1 MB Oral Presentation: Selective Inhibition of ALK2 Signaling Ameliorates Disease in a Novel Model of Iron Refractory Iron Deficiency Anemia (IRIDA) 2.5 MB
9/13/21 at 7:00 AM EDT H.C. Wainwright 23rd Annual Global Investment Conference Click here for webcast
9/10/21 at 11:00 AM EDT Morgan Stanley 19th Annual Global Healthcare Conference Click here for webcast
6/23/21 at 8:00 AM EDT KER-050 Update Click here for webcast Supporting Materials KER-050 Update 1.1 MB
EHA2021 Virtual Congress June 11, 2021 KER-050, an inhibitor of TGF-β superfamily signaling, observed to have a rapid, dynamic, and durable effect on erythropoiesis 4.2 MB ALK2 is a potential therapeutic target in anemia resulting from chronic inflammation 1 MB ALK2 inhibition, a novel therapeutic approach to iron overload 1.5 MB Administration of ALK2 neutralizing antibodies to cynomolgus monkeys led to a sustained decrease in hepcidin, increase in circulating iron and increase in erythrocyte hemoglobin 1.2 MB
KER-050, an inhibitor of TGF-β superfamily signaling, observed to have a rapid, dynamic, and durable effect on erythropoiesis 4.2 MB ALK2 is a potential therapeutic target in anemia resulting from chronic inflammation 1 MB ALK2 inhibition, a novel therapeutic approach to iron overload 1.5 MB Administration of ALK2 neutralizing antibodies to cynomolgus monkeys led to a sustained decrease in hepcidin, increase in circulating iron and increase in erythrocyte hemoglobin 1.2 MB
2021 ATS International Conference Presentation May 14, 2021 2021 ATS International Conference Presentation 646.8 KB
European School of Haematology (ESH) 2nd Translational Research E-Conference March 5, 2021 KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production by Promoting Multiple Stages of Erythroid Differentiation 1.1 MB Targeted ALK2 Inhibition as a Therapeutic Approach to Reducing Hepcidin and Elevating Serum Iron 714.1 KB
KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production by Promoting Multiple Stages of Erythroid Differentiation 1.1 MB Targeted ALK2 Inhibition as a Therapeutic Approach to Reducing Hepcidin and Elevating Serum Iron 714.1 KB
62nd American Society of Hematology (ASH) Annual Meeting and Exposition December 7, 2020 KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production by Promoting Multiple Stages of Erythroid Differentiation 3.1 MB KER-050, a Modified ActRIIA Ligand Trap, Alleviates Cytopenia Arising from Multiple Etiologies 706 KB Administration of KER-047, a Novel ALK2 Inhibitor, Elicited Robust and Sustained Increases in Serum Iron in Healthy Participants 702.1 KB Selective Inhibition of ALK2 Signaling Suppresses Serum Hepcidin and Increases Serum Iron 797.8 KB
KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production by Promoting Multiple Stages of Erythroid Differentiation 3.1 MB KER-050, a Modified ActRIIA Ligand Trap, Alleviates Cytopenia Arising from Multiple Etiologies 706 KB Administration of KER-047, a Novel ALK2 Inhibitor, Elicited Robust and Sustained Increases in Serum Iron in Healthy Participants 702.1 KB Selective Inhibition of ALK2 Signaling Suppresses Serum Hepcidin and Increases Serum Iron 797.8 KB
ASBMR 2020 Annual Meeting Virtual Event September 11, 2020 KER-012, a Novel Activin Receptor Type II Ligand Trap Increased Bone in Mice via a Unique Mechanism of Action 1.5 MB
KER-012, a Novel Activin Receptor Type II Ligand Trap Increased Bone in Mice via a Unique Mechanism of Action 1.5 MB
25th European Hematology Association (EHA) Congress (2020) June 12, 2020 Poster Presentation: Administration of KER-050, a Novel ActRIIA Ligand Trap, to Healthy Participants Elicited Robust and Sustained Increases in Hemoglobin and Platelets 1.3 MB Poster Presentation: Administration of KER-050, a Novel ActRIIA Ligand Trap, to Healthy Participants Elicited Robust and Sustained Increases in Hemoglobin and Platelets (Updated as of April 2021) 1.4 MB Poster Presentation: KER-050, a Novel Modified ActRIIA Ligand Trap, Increases Red Blood Cell Production in Cynomolgus Monkeys 1.3 MB Poster Presentation: KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production and is a Potential Candidate for the Treatment of Ineffective Erythropoiesis 1.1 MB Oral Presentation: Selective Inhibition of ALK2 Signaling Ameliorates Disease in a Novel Model of Iron Refractory Iron Deficiency Anemia (IRIDA) 2.5 MB
Poster Presentation: Administration of KER-050, a Novel ActRIIA Ligand Trap, to Healthy Participants Elicited Robust and Sustained Increases in Hemoglobin and Platelets 1.3 MB Poster Presentation: Administration of KER-050, a Novel ActRIIA Ligand Trap, to Healthy Participants Elicited Robust and Sustained Increases in Hemoglobin and Platelets (Updated as of April 2021) 1.4 MB Poster Presentation: KER-050, a Novel Modified ActRIIA Ligand Trap, Increases Red Blood Cell Production in Cynomolgus Monkeys 1.3 MB Poster Presentation: KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production and is a Potential Candidate for the Treatment of Ineffective Erythropoiesis 1.1 MB Oral Presentation: Selective Inhibition of ALK2 Signaling Ameliorates Disease in a Novel Model of Iron Refractory Iron Deficiency Anemia (IRIDA) 2.5 MB
